Haystack Science
For those interested in science commercialization and how to take early-stage discovery therapeutic assets to market. Weekly updates on preclinical research and the business surrounding provided to you every week.
The Needle Issue #8
ISSUE 8 Welcome to the latest issue of the Needle, a newsletter from Haystack Science helping you understand the latest translational research and goings on in the biotech startup world. This week, we talk about mitochondrial disease, a corner of the gene and base-editing universe that, until recently, had been somewhat neglected, at least in terms of biotech startups. Also, there was the usual harvest of papers describing drug targets and a couple of intriguing drug delivery papers. We...
The Needle Issue #7
ISSUE 7 Welcome to the latest issue of the Needle, a newsletter from Haystack Science on the latest translational research and goings on in the biotech startup world. This week, we take a look at an exciting breakthrough in hematopoietic stem cell (HSC) gene therapy using lentiviral vectors injected directly into the body. There was an unusually large slew of interesting therapeutic papers, including a description from Insilico Medicine of the discovery of an asset from its internal...
The Needle. Issue #6
ISSUE 6 Welcome to the latest issue of the Needle, a newsletter from Haystack Science on preclinical biotech. This week, we look forward to the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago and describe a new mechanism to improve on the efficacy of cancer immunotherapy by inhibiting adenosine transport in lymphocytes. We also highlight new substantial risk investment funding designated to early-stage dementia therapies, as well as state-led funding efforts in cancer...
The Needle. Issue #5
Welcome to the latest issue of the Needle, a newsletter from Haystack Science on preclinical biotech. This week, we take a look at all the action at the American Society of Gene and Cell Therapy Annual Meeting in New Orleans and announcements around next-generation DNA and RNA editing technologies, with one base editing therapy for an ultrarare disease grabbing the headlines. It was a slow week for industry news, but there were a notable number of deals and financings for companies out of...
The Needle Issue #4
Welcome to the latest issue of the Needle, a newsletter from Haystack Science on preclinical biotech. This week, we take a look at advances in lipid nanoparticles and gauge their promise as delivery vehicles for extra-hepatic organs. At the FDA, new Commissioner Martin Makary announced the June launch of AI toxicology models to streamline regulatory oversight and appointed Vinay Prasad, a vocal critic of the accelerated approval pathway, to succeed Peter Marks as CBER Director. The number of...
The Needle Issue #3
Welcome to the latest issue of the Needle, a newsletter from Haystack Science on preclinical biotech. If you are interested in science commercialization and how to take your early-stage discovery to market, this newsletter is for you. We aim to provide quick and insightful updates on preclinical research and the business around it every week. If you find the content helpful, please forward it to your friends and colleagues. This week, we delve into the latest research and startup activity...
The Needle Issue #2
Welcome to the latest issue of the Needle, a newsletter from Haystack Science on preclinical biotech. If you are interested in science commercialization and how to take your early-stage discovery to market, this newsletter is for you. We aim to provide quick and insightful updates on preclinical research and the business around it every week. If you find the content helpful, please forward it to your friends and colleagues. This week, we delve into CD36 as a receptor to help PROTACs cross the...